This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation.
Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation.
In this webinar, you will learn:
• Strategies to support identification, selection, and risk assessment of raw materials throughout the manufacturing process
• Appropriate quality attributes for different raw material uses
• The importance of quality and regulatory documentation provided by the supplier
The subject of cleaning validation in active pharmaceutical ingredient manufacturing plants has continued to receive a large amount of attention from regulators, companies and customers alike.
The integration of Cleaning Validation within an effective Quality System supported by Quality Risk Management Processes should give assurance that API Manufacturing Operations are performed in such a way that Risks to patients related to cleaning validation are understood, assessed for impact and are mitigated as necessary.
It is important that the requirements for the finished manufacturing companies are not transferred back in the process to active pharmaceutical ingredient manufacturers without consideration for the different processes that take place at this stage.
This presentation covers the requirements of Cleaning Validation for a Multipurpose API Manufactuirng Plant
Study on Physico- Chemical Parameters of Waste Water Effluents from Kombolcha...AI Publications
The physicochemical parameters of wastewater collected from five sampling sites were investigated. These parameters were analyzed by standard methods. The pH of the waste water varied from 4.7 to8.2, while the waste water conductivity ranges from 1205.3 to 7130.17 µScm−1. The maximum total dissolved solid was 8100mg/l.and the maximum biological oxygen demand was 2763.35 mg/l. The chemical oxygen demand of the selected samplesites varied widely (772.56–3105.13 mg/l), the nitrate content was found to be maximum insample W5 (166.00mg/l), and the sulfate content was found to be high in samples W1 andW5 (500and 4875mg/l). The chloride and sulphied contents were maximum atsamplesof W3 and W5 their concentrations were8543.45 and 10.7mg/lrespectively. Thephysicochemicalparameters studied in this work were varied between the samplesand almost all parameters studied were higher compared with the permissible limit prescribed by the United States Environmental Protection Agency and World Health Organization.
Risk-based Approach to evaluate Nitrosamines and Elemental Impurities from Si...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3usdjx7
Nitrosamines and elemental impurities are now a concern for regulatory agencies. A key issue related to plastic single-use systems (SUS) is potential leachables from contact materials. For SUS it’s essential to evaluate leachables as well as nitrosamines and elemental impurities risks.
Residual impurities can potentially be introduced into the biopharmaceutical manufacturing process at a variety of stages. Recently, nitrosamines and elemental impurities have been a concern for regulatory agencies. These impurities originate from various raw materials, process chemicals and manufacturing equipment. Single-use systems (SUS) incorporate a number of plastic components. A key concern related to plastic SUS is potential leachable compounds from contact materials. It’s essential to obtain information on leachables as well as nitrosamines and elemental impurities. This webinar looks into how to evaluate nitrosamine and elemental impurity risk related to SUS and filters.
In this webinar, you will:
• Understand of the potential of nitrosamine contamination
• Learn how to leverage industry, supplier, and scientific expertise to assess the risk of elemental impurities taking advantage of ICH Q3D guidance on biologic drug manufacturing
• See a case study using Emprove® Elemental Impurities to help you conduct an efficient elemental impurities safety evaluation D46
Presented by: Janmeet Anant
Senior Regulatory Consultant
Just providing the information on Impurities in drug substances & Drug products to share my view and the collected information from the web for knowledge purpose.
New guidelines relating to elemental impurities from the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities have presented the pharmaceutical industry with new challenges. This new guidance has been developed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.
The subject of cleaning validation in active pharmaceutical ingredient manufacturing plants has continued to receive a large amount of attention from regulators, companies and customers alike.
The integration of Cleaning Validation within an effective Quality System supported by Quality Risk Management Processes should give assurance that API Manufacturing Operations are performed in such a way that Risks to patients related to cleaning validation are understood, assessed for impact and are mitigated as necessary.
It is important that the requirements for the finished manufacturing companies are not transferred back in the process to active pharmaceutical ingredient manufacturers without consideration for the different processes that take place at this stage.
This presentation covers the requirements of Cleaning Validation for a Multipurpose API Manufactuirng Plant
Study on Physico- Chemical Parameters of Waste Water Effluents from Kombolcha...AI Publications
The physicochemical parameters of wastewater collected from five sampling sites were investigated. These parameters were analyzed by standard methods. The pH of the waste water varied from 4.7 to8.2, while the waste water conductivity ranges from 1205.3 to 7130.17 µScm−1. The maximum total dissolved solid was 8100mg/l.and the maximum biological oxygen demand was 2763.35 mg/l. The chemical oxygen demand of the selected samplesites varied widely (772.56–3105.13 mg/l), the nitrate content was found to be maximum insample W5 (166.00mg/l), and the sulfate content was found to be high in samples W1 andW5 (500and 4875mg/l). The chloride and sulphied contents were maximum atsamplesof W3 and W5 their concentrations were8543.45 and 10.7mg/lrespectively. Thephysicochemicalparameters studied in this work were varied between the samplesand almost all parameters studied were higher compared with the permissible limit prescribed by the United States Environmental Protection Agency and World Health Organization.
Risk-based Approach to evaluate Nitrosamines and Elemental Impurities from Si...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3usdjx7
Nitrosamines and elemental impurities are now a concern for regulatory agencies. A key issue related to plastic single-use systems (SUS) is potential leachables from contact materials. For SUS it’s essential to evaluate leachables as well as nitrosamines and elemental impurities risks.
Residual impurities can potentially be introduced into the biopharmaceutical manufacturing process at a variety of stages. Recently, nitrosamines and elemental impurities have been a concern for regulatory agencies. These impurities originate from various raw materials, process chemicals and manufacturing equipment. Single-use systems (SUS) incorporate a number of plastic components. A key concern related to plastic SUS is potential leachable compounds from contact materials. It’s essential to obtain information on leachables as well as nitrosamines and elemental impurities. This webinar looks into how to evaluate nitrosamine and elemental impurity risk related to SUS and filters.
In this webinar, you will:
• Understand of the potential of nitrosamine contamination
• Learn how to leverage industry, supplier, and scientific expertise to assess the risk of elemental impurities taking advantage of ICH Q3D guidance on biologic drug manufacturing
• See a case study using Emprove® Elemental Impurities to help you conduct an efficient elemental impurities safety evaluation D46
Presented by: Janmeet Anant
Senior Regulatory Consultant
Just providing the information on Impurities in drug substances & Drug products to share my view and the collected information from the web for knowledge purpose.
New guidelines relating to elemental impurities from the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities have presented the pharmaceutical industry with new challenges. This new guidance has been developed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.
Current Good Manufacturing Practices: Drug and Biologics Rachel Hamilton
ACI’s FDA Boot Camp has been designed to give products or patent litigators, as well as patent prosecutors, industry in-house counsel, and life sciences investment and securities experts, a strong working knowledge of core FDA competencies.
Presentation complied by Drug Regulations – a not for profit organization from publicly available material form FDA , EMA, EDQM . WHO and similar organizations.
Visit www.drugregulations.org for the latest in Pharmaceutic
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
Current Good Manufacturing Practices: Drug and Biologics Rachel Hamilton
ACI’s FDA Boot Camp has been designed to give products or patent litigators, as well as patent prosecutors, industry in-house counsel, and life sciences investment and securities experts, a strong working knowledge of core FDA competencies.
Presentation complied by Drug Regulations – a not for profit organization from publicly available material form FDA , EMA, EDQM . WHO and similar organizations.
Visit www.drugregulations.org for the latest in Pharmaceutic
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...TGA Australia
2018 has posed many changes for the TGA regulated Pharmaceutical manufacturing industry with the TGA legislating version 13 of the PIC/S guide to GMP for medicinal products which included several changes to both the general chapters and the relevant Annexes. With the implementation transitioning through to the end of December, Manufacturers and Sponsors need to be informed and actively implementing these changes. Additionally, a draft version of Annex 1 has also been released which has the potential to significantly impact sterile manufacturing requirements.
Security Of The Pharmaceutical Supply Chain - Part 4b: The Pharmaceutical Ind...Stuart Silverman
Security Of The Pharmaceutical Supply Chain - Part 4b: The Pharmaceutical Industry Relies Heavily On Sourcing From India & China – India Segment
SPECIAL FOCUS - The environment as a risk to the supply chain.
Process equipment characterization – how standardized extractables data suppo...MilliporeSigma
View the recording here: https://bit.ly/35KIwBb
Biopharmaceutical Industry recently increased adoption of Single-Use systems and components in manufacturing process operations. Drug manufacturers are responsible for the characterization of SU components and systems used for the production to ensure patient safety. SUS Suppliers are encouraged by BPOG and BPSA to provide comprehensive extractables data package to support drug manufacturer’s E&L assessments.
This webinar will give an overview of the E&L evaluation workflow and practical study approaches from both supplier and end-user perspective, in accordance with the latest industry’s standards and upcoming USP <665> requirements. Case studies will be presented on how the data from suppliers are used to mitigate risk associated to SU materials, highlighting the key role of collaboration between the supplier and the drug manufacturer.
Process equipment characterization – how standardized extractables data suppo...Merck Life Sciences
View the recording here: https://bit.ly/35KIwBb
Biopharmaceutical Industry recently increased adoption of Single-Use systems and components in manufacturing process operations. Drug manufacturers are responsible for the characterization of SU components and systems used for the production to ensure patient safety. SUS Suppliers are encouraged by BPOG and BPSA to provide comprehensive extractables data package to support drug manufacturer’s E&L assessments.
This webinar will give an overview of the E&L evaluation workflow and practical study approaches from both supplier and end-user perspective, in accordance with the latest industry’s standards and upcoming USP <665> requirements. Case studies will be presented on how the data from suppliers are used to mitigate risk associated to SU materials, highlighting the key role of collaboration between the supplier and the drug manufacturer.
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...MilliporeSigma
Participate in the interactive webinar: http://bit.ly/PACWebinar
Post-approval changes for biologics manufacturing processes are complicated and challenging with the current global diverse regulatory environment. Here, we will present approaches to make these changes more efficient using a risk-based approach.
Explore our webinar library: www.emdmillipore.com/webinars
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...Merck Life Sciences
Participate in the interactive webinar: http://bit.ly/PACWebinar
Post-approval changes for biologics manufacturing processes are complicated and challenging with the current global diverse regulatory environment. Here, we will present approaches to make these changes more efficient using a risk-based approach.
Explore our webinar library: www.merckmillipore.com/webinars
ICH Q3D - Elemental impurities in pharmaceutical productspi
The ICH has developed the Q3D guideline on elemental impurities. Both the FDA and the EMA encourage the ICH Q3D guideline implementation. All companies will have to be compliant for already authorised and marketed products as of December 2017.
Commercializing antibody-drug conjugates: a CMO’s journeyMilliporeSigma
Watch the webinar here: https://bit.ly/2YLDzTE
This webinar will take you through the story of a CMO preparing for the manufacture of a Commercial Antibody Drug Conjugate (ADC).
Join us to learn about how we grew as a CMO to develop a Commercial ADC program. We will walk through the full timeline from development, process risk assessment and control strategy development and validation, finishing off with preparation for a Commercial ADC Pre-Approval Inspection Audit.
In this webinar you will learn how to:
• Properly structure your development work
• Perform a thorough process risk assessment
• Prepare for pre-approval inspection
Similar to Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving Regulatory Environment (20)
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
Protein viscosity is a major challenge in preparing highly concentrated protein formulations suitable for subcutaneous injection. Recently, the Viscosity Reduction Platform (VRP) was introduced and its technical key features and benefits for formulations were discussed. However, highly viscous solutions do not only pose a challenge when administering a drug to a patient, they can also impose technical limitations in the manufacturing process.
This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.
Find more information about the Viscosity Reduction Platform on our website: https://www.sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
Excipients are used to improve the stability of protein-based therapeutics by protecting the protein against a range of stress conditions such as temperature changes, pH changes, or agitation. Similar stresses are applied to proteins during downstream purification. Shifts in pH during Protein A chromatography, subsequent incubations at low pH for virus inactivation, and changes in conductivity in ion exchange chromatography can lead to aggregation, fragmentation, or other chemical modifications of the therapeutic protein. Given the potential impact on the protein’s structural integrity, there is a need for approaches to reduce the risk presented by the conditions during downstream processing. For example, integration of a solution to prevent aggregation of proteins would be a more efficient strategy than implementing steps to remove multimeric forms.
This white paper highlights the results from a recent paper by Stange et. al., in which protein stabilizing excipients such as polyols, sugars, and polyethylene glycol (PEG4000) were used as buffer system additives. Effect of the excipients on elution patterns, stabilization of the monomer antibody, host-cell protein removal, virus inactivation rates and binding capacity of cation exchange chromatography were explored.
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
Agitation of therapeutic protein solutions during manufacturing, shipping and handling is one of the major initiators for protein aggregation and particle formation during the life history of a protein drug. Adsorption of protein molecules to liquid-air interfaces leads to the formation of highly concentrated protein surface films. The rupture of these protein films due to various mechanical processes can then result in the appearance of protein aggregates and particles in the bulk solution phase.
One technique to stabilize proteins against stress induced by liquid-air interfaces is the use of non-ionic surfactants. About 91% of antibody formulations commercially available in 2021 contained a surfactant. Polysorbate 20 and 80, composed of a hydrophilic polyoxyethylene sorbitan and hydrophobic fatty acid esters, made up the largest part being employed in 87% of said formulations.
Despite their frequent use in parenteral drug products, concerns have been raised for decades about the application of polysorbates as surfactants in biopharmaceutical formulations. Autoxidation of polysorbate, caused by residual peroxides in polysorbates, can damage the proteins and can further drive the oxidative degradation of polysorbate. Chemical and enzymatic hydrolysis of polysorbate may lead to the formation of free fatty acid particles, which may become visible; and both mechanisms eventually lead to the reduction in polysorbate concentration. Therefore, the purpose of the current study was to compare various molecules for their capabilities to reduced agitation-induced protein aggregation and particle formation; and furthermore, investigate their underlying protein stabilizing mechanisms.
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous injection.
This whitepaper examines how combining an amino acid with a second viscosity-reducing excipient circumvents adverse effects on protein stability and improves viscosity-reducing capacity.
To find more information about the Viscosity Reduction Platform, please visit our website: https://sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
Watch the presentation of this webinar: https://bit.ly/3Pjpjvr
Highlights of this webinar:
- Surface plasmon resonance as a powerful tool for biologic characterization including mAbs and ADCs.
- SPR allows rapid binding analysis in real time without using labels for SARS-CoV-2 receptor binding domain mutations.
- Kinetic data is indicative of possible neutralizing activity allowed assessment of neutralizing ability of therapeutic monoclonal antibodies.
- The application can provide preliminarily efficacy information and facilitated mAbs/ACDs candidate selection process
Detailed description:
Characterization of therapeutic monoclonal antibodies (mAbs) or Antibody drug conjugates (ADCs) is challenging due to their ability to bind to a variety of proteins via their Fc and Fab domains, giving rise to diverse biological functions associated with each domain. The Fc domain of mAbs interacts with Fc receptors with varying affinities, which can influence biological processes such as Complement-dependent cytotoxicity (CDC) and Antibody-dependent cellular cytotoxicity (ADCC), transcytosis, phagocytosis, and/or serum half-life.
An important characteristic of an antibody is its Fc effector function. Antibodies can be engineered to obtain desired binding of the Fc region to Fc receptors expressed on effector cells. Hence, it is crucial to evaluate the binding interaction of mAbs/ADC with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.
Surface Plasmon Resonance (SPR) is a powerful technique to establish binding kinetics in real-time, label free, and high sensitivity with low sample consumption. Along with target antigen binding, it is crucial to evaluate the binding interaction of antibodies and ADCs with Fc receptors. Our SPR case studies investigated the impact on binding kinetics of ADCs with different linkers and the binding interactions of SARS-CoV-2 spike protein variants and evaluated the neutralizing ability of therapeutic mAbs. SPR characterisation can be facilitated in all stages of the product life cycle to ensure the quality and safety of mAbs and ADCs.
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
Regulatory expectation does require patient safety evaluations with supporting data for manufacturing components that directly come into contact with drug manufacturing process streams. Readily available extractables data can help manufacturers using singleuse technology to accelerate product qualifications, risk assessments and process optimization
This white paper guides you on how to save time and resources with supplier-provided single-use system extractables data and gives you an overview about the overall strategy for Extractables & Leachables. At the end you will find a case study.
Find more information about filters and single-use components on our website: https://www.sigmaaldrich.com/DE/en/services/product-services/emprove-program/emprove-filter-and-single-use-component-portfolio
Watch the recording of this presentation here: https://bit.ly/3zTOpe4
Detailed description:
SARS-CoV-2 showed us that technology supports us during our inspection activity even if on-site visits are not possible. Travel restrictions of various kinds will remain a risk in the future. The use of new technologies has shown that inspections and audits can be carried out despite these restrictions. We will focus on what possibilities the new technologies offer and take a look at the future of inspections and audits.
In this webinar, you will learn:
• Regulatory overview of remote audits
• The technologies needed to support the audit process
• What types of inspections are possible with the use of these technologies
• How audits may look in the future
Presented by:
Daniel Buescher, Product Manager - Digital Solutions
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
Watch the recording of this presentation here: https://bit.ly/3SqOsoP
Novel therapies, including cell and gene therapies, continue to be central to innovation in healthcare and represent the fastest growing area of therapeutic medicine. As a consequence, the number of gene therapies undergoing clinical trials has increased significantly in the last five years.
Manufacturing processes for these novel therapeutics are very complex with a high risk of contamination. Regulatory agencies world-wide have responded by issuing guidance to outline their expectations for development and manufacture of cell and gene therapies. Currently, regulatory guidance is not harmonized globally and can often lead to confusion within industry and increased risk of non-compliance.
In this webinar, we'll answer:
• Which regulatory guidelines do you need to comply for your INDs?
• When do you start implementing GMPs and validated assays?
• How do you get your QC testing strategy ‘right the first time’?
• How do you ensure testing is not your rate limiting step for the IND submission?
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Dr. Alison Armstrong, Sr. Director, Technical and Scientific Solutions
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3RijkHC
Detailed description:
Imagine you’ve just completed a manufacturing run for your viral vector. Identity testing is performed to confirm the vector sequence. But when the results come back the data reveals unexpected sequence variants! With an appropriate risk mitigation testing strategy, this situation can be prevented.
The situation described above is not hypothetical, and happens more that you think, costing valuable time and resources.
Investigatory testing has shown that sequence variants present in starting materials (e.g. plasmids) are likely to make their way to the final product. Adequate identification of low-level variants with an appropriately sensitive method is critical in ensuring the quality of the final product. A risk-based testing strategy, in the context of identity, for viral vector manufacturing will be presented, focusing on key testing points. NGS assays for identity and variant detection will be highlighted due to their extremely sensitive nature compared to traditional approaches.
In this webinar, we'll explore:
• Regulatory requirements for identity testing
• NGS applications for identity testing as compared to traditional methods
• A case study on the impact of not establishing a proper risk-based testing strategy
Presented by: Bradley Hasson, Director of Lab Operations for NGS Services
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3A2WcH4
The application of polymer excipients in 3D printing manufacturing is usually limited due to the concerns of filament strength, high processing temperature and large scale manufacturing.
Latest technology developments are targeting a direct melt deposition to simplify the process and enable a constant and efficient process. Two different processing approaches will be presented:
The advanced melt drop deposition, where individual three dimensional geometries can be created by depostition of polymer droplets and the MED® 3D printing technology which allows by precise layer-by-layer deposition to produce objects with well-designed geometric structures.
In this webinar, you will learn:
• Latest advancements of melt based 3D printing approaches
• Application examples for the individual technologies
• Deep dive in the MED® 3D printing technology to design dedicated drug release profiles
Presented by:
Dr. Thomas Kipping, Head of Drug Carriers
Dr. Xianghao Zuo, Deputy Director of R&D, Triastek
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3NDNIKe
Automated, fit-for-purpose tools are essential in CAR-T processing to support sustainable manufacturing of clinical and market-approved cell therapy products. This webinar will discuss how the ekko™ Acoustic Cell Processing System uses acoustic technology as a touchless approach to manipulate cells, enabling a modular tool across the CAR-T manufacturing workflow. Typical performance of templated ekko™ System processes for DMSO washout of leukapheresis material, low volume and high cell concentrate for electroporation preparation, and harvest of expanded T cells will be reviewed.
This webinar will also give an early glimpse at the ekko™ Select System for unmatched T cell selection.
In this webinar, you will:
• Uncover how the ekko™ System supports the broad industrialization of cell therapy, with particular focus on how to achieve low volume, high concentrate cell product for critical transduction and transfection steps
• Discover how ekko™ System for wash and concentrate processes throughout the cell therapy workflow achieve high cell recovery, viability, and effective residual removal
• Preview to ekko™ Select, our cell therapy selection platform, to achieve unmatched ease-of-use with direct processing from leukopaks reducing the need for preparation steps
Presented by:
Benjamin Ross-Johnsrud, Acoustic Technology Expert
Robert Scott, Mechanical Engineer III
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3t7X9tg
How does the ICH Q5A revision impact viral safety strategies for biologics?
Biologics continue to grow at a fast pace. Manufactured using cell lines of human or animal origin, these are at risk of viral contamination making safety strategies critical. A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory expectation. ICH Q5A, the globally-harmonized guideline outlines the expectations. ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We’ll discuss the expected changes and potential impact on viral safety strategies with case studies and examples.
In this webinar, you will learn about:
• The Importance of virus testing in biologics products
• Regulatory landscape, expectations for the Q5A revision
• What's new and changing
• Examples of alternate testing schedules, impact on viral clearance
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Alison Armstrong, PhD, Sr. Director, Technical and Scientific Solutions
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3adaxWh
When implementing new automation systems, organizations must consider things like deployment time, user adoption, and costs.
They must also consider the cost of doing nothing – that is, what competitive advantage is lost in standing still? What time and quality is lost in repetitive, manual tasks rather than an automated, digital workflow? What operational efficiencies are lost?
In this webinar we examine how a product, process, and system agnostic automation platform can be deployed faster than traditional system specific software while bringing greater operational efficiencies (in many cases over 30% improvement).
To remain competitive in the market, biopharma manufacturers must adopt automation and digital technologies, but most plants still have island of automation consisting of independently functioning, standalone unit operations. This results in operational inefficiency, regulatory concerns, and a poor understanding of the process and product life cycle.
Taking the first, right step must include considering risks, costs, timelines, and technology alternatives. Traditional automation approaches tied to specific systems, processes, and products are, by their nature, limited; while an agnostic platform will address current biomanufacturing business challenges and ensure future readiness. With the right platform, a phased automation implementation can yield operational efficiency gains of up to 30% and improved product quality and regulatory compliance.
In this webinar, let's explore:
• Challenges of automation and digital technology adoption
• What a product, process, and system agnostic platform entails
• Applications and benefits of a process orchestration platform
• Ensuring future readiness with process orchestration
Presented by:
Braj Nandan Thakur, Global Product Manager - Automation
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3Nbb5ug
Get insights and best practices from a multinational team establishing a platform for vaccine production. See how a long-term collaboration on a bench-scale process used to produce a Virus Like Particle (VLP) vaccine for SARS-CoV-2 was successfully converted to a robust GMP-compatible, scalable process.
The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with Technovax and Innovative Biotech in which a scalable VLP vaccine platform was optimized for use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine.
In this webinar, you will learn:
• About building a priceless collaborative network with integrated solutions
• Virus-Like Particle Vaccines
• Process Development Overview and Challenges
• Pre-clinical Results and Next Steps
Presented by:
Jose M. Galarza, PhD,
President and Founder of TechnoVax
Naomi Baer,
Business development consultant, Emerging Biotech, BioProcess division
Youssef Gaabouri, Eng. ,
Associate Director, Head of Sales Middle East & Africa, BioProcess division
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQf0qv
In the single-use bioprocess industry, X-ray irradiation warrants consideration as an alternate sterilization technology. Using a risk-based qualification testing strategy is important when evaluating and implementing equivalent ionizing irradiation sterilization methods.
The urgent need for life-saving therapies as a result of the global pandemic has reinforced the criticality of flexibility in pharmaceutical manufacturing, including sterilization. The single-use bioprocess industry traditionally has employed gamma irradiation sterilization. X-ray irradiation is being considered as an additional sterilization technology for business and supply continuity. We will share a risk-based qualification testing strategy including Extractables and data generated to support comparability of gamma irradiation and X-ray irradiation as equivalent ionizing irradiation sterilization methods.
In this webinar, you will learn about:
• The comparison of gamma and X-ray irradiation sterilization
• A risk-based qualification test strategy
• Data evaluation of gamma versus X-ray sterilized single-use components
Presented by:
Monica Cardona,
Global Senior Program Manager
Paul Killian, Ph.D.,
R&D Director, Analytical Technologies
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3MJ4u9V
Testing for presence of replication competent adenovirus (RCA) is a key component to ensure patient safety and a requirement for all biologicals manufactured using adenoviral vectors. For many adenoviral-based products, the RCA assay is a rate-limiting assay for lot release.
Join this webinar to learn about a rapid RCA detection assay currently in development, which combines a 7-day culture assay with a highly sensitive molecular endpoint specific for RCA. The method can detect presence of as little as 1 RCA in adenoviral vector material at an approximate concentration of 5x107 - 2x108 vector particles (VP)/mL, making it a suitable method to meet regulatory requirements while accelerating your lot release timelines.
In this webinar, you will learn about:
• Regulatory framework for adenoviral vector products
• Considerations for lot release testing of adenoviral-based therapies
• Advantages of a rapid method for RCA testing on production lot material
Presented by:
Axel Fun, Ph.D.,
Principal Scientist
Alberto Santana, MBA,
Product Manager, Biologics Biosafety Testing
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQyN7K
Bitter medicines are an important issue, especially for pediatric applications. As several APIs have bitter tasting components, high intensity sweeteners for taste optimization are of great interest. Join our webinar to discover our new sweetener toolbox enabling safe and stable formulations.
Mask bitter aftertaste for a sweeter pill to swallow! Patients’ compliance and the therapeutic benefit are supported by a pleasant taste of pharmaceutical formulations. With the high intensity sweeteners Neotame and Sucralose, you have efficient tools at hand which are superior to other sweeteners in many aspects:
• excellent sugar-like taste profile
• outstanding sweetness factors
• use effectiveness
• enhanced stability
We will present our new toolbox of two high performance sweeteners and focus on aspects of stability, safety, the application in various dosage forms, and market perception.
In this webinar, you will learn:
• How to optimize the patients' taste experience of your pharmaceuticals
• How sweeteners can be differentiated by their sensory profiles and features
• How our new product offering Neotame can be effectively used in your targeted formulations
Presented by:
Almut von der Brelie,
Senior Manager Strategic Marketing
Excipients for Solid Applications
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
This whitepaper by Dr. Daniel Joseph Price outlines how poorly soluble drug formulations can be designed using the developability classification system (DCS).
The DCS identifies the root cause of low solubility and enables lean, cost-effective and effective formulations to be developed.
#solubility #pharmaceuticalmanufacturing #oralsoliddosage #drugdevelopment
In this webinar, you will learn about:
The advantages of using advanced intermediates to develop ADC therapies
How to increase ADC solubility and efficiency
Fast, small-scale ADC library generation
Seamless supply chain with reduced complexity and regulatory support
The ADCore product line offers versatile intermediates that simplify the synthesis of common ADC payloads (dolastatins, maytansinoids, and PBDs) by greatly reducing the number of synthetic steps. This translates to savings in development and manufacturing costs and shorter timelines to the clinic. To address the poor solubility of many ADC payloads, ChetoSensar™ was developed to significantly increase the hydrophilicity of the drug linker, which has been shown to also substantially increase the efficacy of ADCs and broaden the therapeutic window.
Lastly, the ADC Express™ service leverages conjugation chemistry and analytical expertise to help design and quickly synthesize sets of potential ADC therapies suitable for screening to simplify candidate selection and get ADC therapies to market faster.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Immunity to Veterinary parasitic infections power point presentation
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving Regulatory Environment
1. Merck KGaA
Darmstadt, Germany
January 18, 2018
Douglas Bowman
Identifying Appropriate-Quality
Pharmaceutical Raw Materials in an
Evolving Regulatory Environment
2. 2 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
The life science business of
Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma
in the U.S. and Canada.
3. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 20183
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
4. Raw Materials Challenges
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 20184
Raw materials inherently introduce risk
Bioprocesses sensitive to variability and present different risks
Traceability and control of raw materials through entire supply chain
5. Raw Materials Challenges
5 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
How do we identify
”““appropriate quality”?
Regulations require drug manufacturers
to assess and mitigate risk throughout
their entire processes, including raw
materials
No clear, prescriptive quality definitions
exist for “non-regulated” raw materials
6. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 20186
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
7. Constantly Evolving Regulations and Guidance
2
0
0
5
ICH
Q
8
Pharm
aceutical
D
evelopm
ent
&
ICH
Q
9
Q
uality
R
isk
M
anagem
ent
2
0
1
3
2
0
1
5
ICH
Q
3D
Elem
ental
Im
purities
CTD
Form
at
ICH
Q
11
D
evelopm
ent
&
M
anufacture
of
D
rug
Substances
EU
2
01
1/62
“falsified
m
edicine
directive”
IP
EC
-
P
Q
G
G
M
P
for
P
harm
aceuticalExcipients
EU
2015/C95/02
“Form
alized
R
isk
A
ssessm
ent”
for
Excipients
First
EX
CiPA
CT™
Certification
2
0
0
3
2
0
0
6
2
0
1
2
2
0
0
8
IPEC
TU
PP
G
uide
EM
A
/CH
M
P/B
W
P/187
338/2014
Process
V
alidation
of
B
iotech
A
PIs
2
0
1
8
ICH
Q
12
Lifecycle
M
anagem
ent
2
0
1
1
ICH
Q
10
Pharm
aceutical
Q
uality
System
R
evision
of
EU
D
R
A
LEX
V
ol4
Chapter
5
2
0
1
6
7 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
8. ICH Q11:
•Development and Manufacture of Drug Substances (Chemical Entities and
Biotechnological/Biological Entities)
•Clarifies and explains ICH Q8, Q9, Q10 & CTD
•Describes the need for comprehensive risk assessment of the entire drug product
manufacturing process, defining critical control parameters, quality by design
•Specifically states the need to include raw and starting materials in this assessment,
highlighting biological processes, but does not set specific quality standards for raw
materials
Guidelines For Raw Materials - Example
8 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
9. EUDRALEX Vol 4, Part 1, Chapter 5:
•Revision to the EU Rules Governing GMP for Medicinal Products – Production
•Two major changes: one was the addition of qualification of suppliers of starting materials
•Introduces strict requirements for the selection, qualification, approval and maintenance
of suppliers of starting materials
Guidelines For Raw Materials - Example
9 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
10. EMA/CHMP/BWP/187338/2014:
•Guideline on process validation for the manufacture of biotechnology-derived active
substances, and data to be provided in the regulatory submission
•Risk assessment, supported by documentation, to control raw material impact on quality
of drug substance
•This should be evaluated already at the stage of manufacturing process development and
validation
Guidelines For Raw Materials - Example
10 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
11. EU 2015/C95/02:
•Guideline on the formalized risk assessment for ascertaining the appropriate good
manufacturing practice for excipients of medicinal products for human use
•The manufacturing authorization holder to define appropriate GMP for their specific use
and then ensure the excipients are suitable for use.
•Risk assessment/management documentation should be available on site for review by GMP
inspectors.
•Relevant information from the risk assessment should be shared with the excipient
manufacturer to facilitate continuous improvement.
This risk assessment guideline for excipients could play a useful role in the
selection of other raw materials
Guidelines For Raw Materials - Example
11 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
12. Risk Assessment for Excipients: (Useful for other raw materials?)
Guidelines For Raw Materials - Example
12 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
Drug Product ManufacturerDrug Product Manufacturer
Determine and assess the risks for each materialDetermine and assess the risks for each material
Consider the Application
of the Material
Consider the Application
of the Material
• Dosage form & Route of administration
• Functionality
• Potential impact on critical quality
attributes
• Quantity, daily intake
• Dosage form & Route of administration
• Functionality
• Potential impact on critical quality
attributes
• Quantity, daily intake
Consider Risks from
Manufacture / Supply
Consider Risks from
Manufacture / Supply
• Quality Management System
• Contamination potential
• Impurities
• TSE, viral safety
• Microbiological / endotoxin
• Equipment / facilities
• Supply chain complexity
• Quality Management System
• Contamination potential
• Impurities
• TSE, viral safety
• Microbiological / endotoxin
• Equipment / facilities
• Supply chain complexity
13. Regulatory Considerations - Summary
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201813
Risk Assessment and Quality By Design are important focus topics for
regulatory agencies, includes raw materials
Control of manufacturing process parameters and raw material quality is
necessary to mitigate risks
Demands a deep understanding by the drug manufacturer of raw material
attributes and supply chains.
Bioprocess technologies further drive the need for higher supply chain
transparency and standardization.
General guidance is given for “non-regulated” or “evolving regulation” raw
materials, but no detailed quality attributes are described.
1
2
3
4
5
14. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201814
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
15. Drug Manufacturing Process Steps
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201815
LARGE
MOLECULE
SMALL
MOLECULE
“Evolving Regulation”
Raw Materials:
Upstream & Process
“Regulated” Starting
Materials:
Downstream &
Formulation
16. Complex Manufacturing Systems Need Detailed Risk Assessment
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201816
Impurities From
Input Materials
Drug Product and
Manufacturing
Process Dependent
17. Transparency of supply chain and quality system
• Visibility of supply chain to original manufacturer
• Quality system information for qualification
• Complete documentation package, ideally readily available
Consistency of product
• Robust, controlled manufacturing processes and analytical
methods
• Change management, change notifications
• Fit-for-purpose testing and release specifications
• Shelf-life information
Not over-engineered
• Reduce complexity
“Evolving Regulation” Raw Material Needs
17 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
Reminder: Usefulness of risk assessment for
excipients principles
18. Proposed Quality Attributes: Summary Table I
18 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
19. Proposed Quality Attributes: Summary Table II
19 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
20. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201820
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
21. Sourcing GMP and compendial chemicals should ensure high levels of product quality and control, but they
are not always the perfect fit for processing use:
•Using APIs and Excipients as process chemicals might add unnecessary complexity and cost.
•Compendial specifications are not designed for processing applications; many suppliers are not equipped
to develop new analytical methods to support these needs
•Compendial and GMP compliance claims are not always clear
•Focusing only on GMP suppliers and products limits choice
Work with specialized life science suppliers who understand different technologies and applications and
offer a range of relevant quality standards.
GMP/Compendial Grades
21 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
22. Suppliers From Emerging Markets
22 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
Approaches to suppliers from emerging markets can be extreme; finding the correct balance is critical:
•A strategy for these regions is important since they represent a high percentage of global capacity of
many essential product groups.
•Supply chains are often difficult to penetrate, so regional QA and Procurement presence is a strong
advantage.
•Further processing and purification of raw materials can mitigate risk.
•Working with a large specialized supplier who has this regional presence and capability can be an effective
approach.
Handled correctly, suppliers and raw materials from emerging markets are an important component of
the supply chain.
23. Drug manufacturers are encouraged to procure starting materials from the original manufacturer wherever
possible (e.g., EU GMP Guide, Part 1, Chapter 5.)
However, it is not always practical or even possible to buy from the original manufacturer:
•In particular, large industrial manufacturers will often not entertain the quality needs of pharma
customers.
•Their distributors are not always set up to properly handle requests and provide documentation.
•Site audits, quality agreements and change notifications are difficult to establish.
Regulations do not insist on procurement from original manufacturers, as long as full traceability is
available.
Specialized suppliers actively qualify and audit original manufacturers, and additionally offer
reprocessing, repackaging, QC and documentation.
Original Manufacturer Requirement
23 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
24. Collecting documents and information from suppliers is one of the biggest causes of delay in raw material
qualification.
•Target suppliers within the life science industry.
•Make clear at the start what documentation you will need for qualification and ongoing material
management, get the supplier's commitment.
•One-off questionnaires are relatively easy to complete; make sure there is a sufficient quality system in
place to support the documents and manage change.
•Start discussions on quality agreements as early as possible in the qualification process
Facilitate the qualification process and save time by working with a supplier who already has detailed
documentation packages prepared and readily available
Documentation
24 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
25. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201825
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
26. Emprove®
Evolve
Non-GMP, but with GMP concepts and
elements
Evolving regulatory needs
NEW Emprove®
Chemicals category to
be added in 2018
SAFC PharmaGrade™
(~120 products)
Integration 2018-2020
Emprove®
Essential
GMP (IPEC)
Moderate risk applications
Emprove®
Expert
GMP (IPEC)
Higher risk applications
Emprove®
API
GMP (ICH Q7)
Existing Emprove®
Chemicals categories
(~400 products)
Emprove®
Program – Chemicals Categories
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201826
27. Emprove®
Chemicals Dossier Library
Emprove®
Documentation
Operational Excellence Dossier
Product quality report
Elemental impurity information
Analytical procedure
Supports process optimization
Material Qualification Dossier
In line with CTD chapter 3 quality
(adapted for excipients)
General information
Manufacture
Characterization
Control of drug substance
Reference standard
Materials
Container closure system
Stability
Information to start a material
qualification
Quality Management Dossier
Quality Self Assessment
Audit report summary
Supply chain Information
Stability data
Answers questions during risk
assessment
free of charge
charged charged
Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201827
Emprove®
Suite: Full online access to all dossiers
28. PharmaGrade™ Product Regulatory Datasheet
− Product Name, Part Number, CAS No., MW
− Specifications
− Product Origin
− Site of Manufacturing
− Process Information
− Risk Statements
− Shelf-life/Stability Statement
Site Quality Overview
Site and Supply Chain Security Overview
Certificates (ISO, GMP, etc.)
PharmaGrade™ Documentation
28 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018
Direct web access to documentation for in-house manufactured products
Controlled access to third-party manufactured products (under CDA)
29. Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 201829
Agenda
Regulatory considerations for raw materials
Raw material quality attributes for different applications
Strategies/tips for selection of suppliers and raw materials
Emprove®
Program
Summary
Introduction
30. • Regulations require drug manufacturers to perform significant risk assessment and mitigation strategies
for raw materials.
• Supply chains and manufacturing technologies are increasingly complex.
• Evolving regulations and technologies are driving the need for greater transparency and
standardization.
• No clear quality standard exists for many raw materials.
• Up-to-date, accurate information in a convenient format is crucial.
Working with an expert partner can help you speed your way through the regulatory maze.
Summary
30 Webinar: Raw Materials in Evolving Regulatory Environment | D Bowman | January 18 2018